Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

SGLT2 inhibition with empagliflozin improves coronary microvascular function and cardiac contractility in prediabetic ob/ob−/− mice
Damilola D. Adingupu, Sven Göpel, Julia Grönros, et al.
Cardiovascular Diabetology (2019) Vol. 18, Iss. 1
Open Access | Times Cited: 141

Showing 1-25 of 141 citing articles:

Mechanisms of Cardiorenal Effects of Sodium-Glucose Cotransporter 2 Inhibitors
Thomas A. Zelniker, Eugene Braunwald
Journal of the American College of Cardiology (2020) Vol. 75, Iss. 4, pp. 422-434
Closed Access | Times Cited: 413
Coronary Microvascular Dysfunction Across the Spectrum of Cardiovascular Diseases
Marco Giuseppe Del Buono, Rocco A. Montone, Massimiliano Camilli, et al.
Journal of the American College of Cardiology (2021) Vol. 78, Iss. 13, pp. 1352-1371
Open Access | Times Cited: 372
Empagliflozin Attenuates Non-Alcoholic Fatty Liver Disease (NAFLD) in High Fat Diet Fed ApoE(-/-) Mice by Activating Autophagy and Reducing ER Stress and Apoptosis
Narjes Nasiri‐Ansari, Chrysa Nikolopoulou, Katerina Papoutsi, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 2, pp. 818-818
Open Access | Times Cited: 218
Distinct Types of Cell Death and the Implication in Diabetic Cardiomyopathy
Yun Chen, Yuyun Hua, Xinshuai Li, et al.
Frontiers in Pharmacology (2020) Vol. 11
Open Access | Times Cited: 166
Sodium–glucose cotransporter 2 inhibitor Dapagliflozin attenuates diabetic cardiomyopathy
Mohamad Arow, Maayan Waldman, Dor Yadin, et al.
Cardiovascular Diabetology (2020) Vol. 19, Iss. 1
Open Access | Times Cited: 161
Empagliflozin protects heart from inflammation and energy depletion via AMPK activation
Chintan N. Koyani, Ioanna Plastira, Harald Sourij, et al.
Pharmacological Research (2020) Vol. 158, pp. 104870-104870
Closed Access | Times Cited: 146
An Overview of the Cardiorenal Protective Mechanisms of SGLT2 Inhibitors
Teresa Salvatore, Raffaele Galiero, Alfredo Caturano, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 7, pp. 3651-3651
Open Access | Times Cited: 142
Empagliflozin attenuates cardiac microvascular ischemia/reperfusion injury through improving mitochondrial homeostasis
Rongjun Zou, Wanting Shi, Junxiong Qiu, et al.
Cardiovascular Diabetology (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 81
SGLT2 inhibitor dapagliflozin reduces endothelial dysfunction and microvascular damage during cardiac ischemia/reperfusion injury through normalizing the XO-SERCA2-CaMKII-coffilin pathways
Li Ma, Rongjun Zou, Wanting Shi, et al.
Theranostics (2022) Vol. 12, Iss. 11, pp. 5034-5050
Open Access | Times Cited: 81
Insights into SGLT2 inhibitor treatment of diabetic cardiomyopathy: focus on the mechanisms
Keming Huang, Xianling Luo, Bin Liao, et al.
Cardiovascular Diabetology (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 45
Coronary microvascular dysfunction: A review of recent progress and clinical implications
Rajan Rehan, A. Yong, M. Ng, et al.
Frontiers in Cardiovascular Medicine (2023) Vol. 10
Open Access | Times Cited: 41
SGLT2 inhibitors: from glucose-lowering to cardiovascular benefits
Alberto Preda, Fabrizio Montecucco, Federico Carbone, et al.
Cardiovascular Research (2024) Vol. 120, Iss. 5, pp. 443-460
Open Access | Times Cited: 31
Endothelial dysfunction in vascular complications of diabetes: a comprehensive review of mechanisms and implications
Dongrong Yang, Meng‐Yan Wang, Chenglin Zhang, et al.
Frontiers in Endocrinology (2024) Vol. 15
Open Access | Times Cited: 29
Characterization of the inflammatory‐metabolic phenotype of heart failure with a preserved ejection fraction: a hypothesis to explain influence of sex on the evolution and potential treatment of the disease
Milton Packer, Carolyn S.P. Lam, Lars H. Lund, et al.
European Journal of Heart Failure (2020) Vol. 22, Iss. 9, pp. 1551-1567
Open Access | Times Cited: 127
Off-target effects of sodium-glucose co-transporter 2 blockers: empagliflozin does not inhibit Na+/H+ exchanger-1 or lower [Na+]i in the heart
Yu Jin Chung, Kyung Chan Park, Sergiy Tokar, et al.
Cardiovascular Research (2020) Vol. 117, Iss. 14, pp. 2794-2806
Open Access | Times Cited: 115
Empagliflozin prevents doxorubicin-induced myocardial dysfunction
Jolanda Sabatino, Salvatore De Rosa, Laura Tammè, et al.
Cardiovascular Diabetology (2020) Vol. 19, Iss. 1
Open Access | Times Cited: 106
Empagliflozin improved systolic blood pressure, endothelial dysfunction and heart remodeling in the metabolic syndrome ZSF1 rat
Sin‐Hee Park, Muhammad A. Farooq, S. Gærtner, et al.
Cardiovascular Diabetology (2020) Vol. 19, Iss. 1
Open Access | Times Cited: 103
Autophagy-dependent and -independent modulation of oxidative and organellar stress in the diabetic heart by glucose-lowering drugs
Milton Packer
Cardiovascular Diabetology (2020) Vol. 19, Iss. 1
Open Access | Times Cited: 98
Impact of sodium glucose cotransporter 2 (SGLT2) inhibitors on atherosclerosis: from pharmacology to pre-clinical and clinical therapeutics
Zhenghong Liu, Xiaoxuan Ma, Iqra Ilyas, et al.
Theranostics (2021) Vol. 11, Iss. 9, pp. 4502-4515
Open Access | Times Cited: 98
Angiotensin II-induced upregulation of SGLT1 and 2 contributes to human microparticle‐stimulated endothelial senescence and dysfunction: protective effect of gliflozins
Sin‐Hee Park, Eugenia Belcastro, Hira Hasan, et al.
Cardiovascular Diabetology (2021) Vol. 20, Iss. 1
Open Access | Times Cited: 94
Autophagy stimulation and intracellular sodium reduction as mediators of the cardioprotective effect of sodium–glucose cotransporter 2 inhibitors
Milton Packer
European Journal of Heart Failure (2020) Vol. 22, Iss. 4, pp. 618-628
Open Access | Times Cited: 85
Effects of Sodium-Glucose Co-Transporter 2 Inhibitors on Vascular Cell Function and Arterial Remodeling
William Durante, Ghazaleh Behnammanesh, Kelly J. Peyton
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 16, pp. 8786-8786
Open Access | Times Cited: 85
Differential Pathophysiological Mechanisms in Heart Failure With a Reduced or Preserved Ejection Fraction in Diabetes
Milton Packer
JACC Heart Failure (2021) Vol. 9, Iss. 8, pp. 535-549
Open Access | Times Cited: 76
Cardiovascular Benefits from Gliflozins: Effects on Endothelial Function
Teresa Salvatore, Alfredo Caturano, Raffaele Galiero, et al.
Biomedicines (2021) Vol. 9, Iss. 10, pp. 1356-1356
Open Access | Times Cited: 64
Coronary Microvascular Dysfunction in Diabetes Mellitus: Pathogenetic Mechanisms and Potential Therapeutic Options
Teresa Salvatore, Raffaele Galiero, Alfredo Caturano, et al.
Biomedicines (2022) Vol. 10, Iss. 9, pp. 2274-2274
Open Access | Times Cited: 54
Page 1 - Next Page

Scroll to top